Oxford BioMedica

Oxford BioMedica advanced gene therapy techniques.

Contact Details: Robert Robertson AvenueThe Oxford Science Park Oxford Oxfordshire OX4 4 GA United Kingdom Tel: +44 1865 783 000 Fax: +44 1865 783 001 Email: p.nolan@oxfordbiomedica.co.uk WWW: www.oxfordbiomedica.co.uk/

Loading...

Recent Publications by Oxford BioMedica:
Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. The cancer vaccine TroVax, modified vaccinia Ankara encoding the...	20th June, 2009	Oxford BioMedica (UK) Ltd, Medawar Centre, Oxford Science Park, Oxford,	Int Immunol. 2008 Aug;20(8):1057-66. Epub 2008 Jun 20. DOI Direct Link
Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. Large-scale production of gene therapeutics comprising equine infectious...	6th March, 2009	Oxford BioMedica (UK) Ltd, Medawar Centre, Robert Robinson Avenue, The	Gene Ther. 2009 Jun;16(6):805-14. Epub 2009 Mar 5. DOI Direct Link
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Modified vaccinia Ankara (MVA) encoding the tumor antigen 5T4 (TroVax) has...	3rd September, 2008	Oxford BioMedica (UK) Ltd, The Medawar Centre, Oxford Science Park, Oxford	Cancer Immunol Immunother. 2008 Jul;57(7):977-86. DOI Direct Link
Analysis of factor VIII mediated suppression of lentiviral vector titres. Effective gene therapy for haemophilia A necessitates a vector system that...	8th August, 2008	Oxford BioMedica (UK) Ltd, Medawar Centre, The Oxford Science Park,	Gene Ther. 2008 Feb;15(4):289-97. Epub 2007 Nov 29. DOI Direct Link
Development of photoreceptor-specific promoters and their utility to investigate EIAV lentiviral vector mediated gene transfer to photoreceptors. BACKGROUND: We wanted to investigate the ability of recombinant equine...	2nd April, 2008	Oxford BioMedica (UK) Ltd., Medawar Centre, Robert Robinson Avenue, Oxford	J Gene Med. 2007 Dec;9(12):1015-23. DOI Direct Link
→View more Oxford BioMedica research publications.

Press Releases on Oxford BioMedica:
Reportlinker Adds Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists	16th October, 2009	Reportlinker	-- additional comments with a hyperlink leading to the source of information. Index -- 2008 Sales of VEGF/R Antagonists -- VEGF-R Agonists -- Cardiovascular
The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica	9th May, 2009	Bavarian Nordic A/S	KVISTGARD, Denmark, May 9 /PRNewswire-FirstCall/ -- Oxford Biomedica's second attempt to dismiss Bavarian Nordic's patent infringement suit in the United States has failed. Instead of
Sanofi-aventis Announces Good First-quarter 2009 Performance	29th April, 2009	Sanofi-aventis	Change at Change on a constant Q1 2009
Bavarian Nordic Publishes its Annual Results 2008	27th March, 2009		KVISTGAARD, Denmark, March 27 /PRNewswire/ -- Today Bavarian Nordic published the company's Annual Report 2008. The report is available on the company's website: http://www.bavarian-nordid
Bavarian Nordic's Case Against Oxford BioMedica	12th January, 2009		KVISTGARD, Denmark, January 12 /PRNewswire/ -- Bavarian Nordic owns several United States patents relating to an attenuated strain of the company's core technology, MVA-BN(R), which is the basis

BioNews Results for Oxford BioMedica:
Oxford BioMedica looks to expand market for cancer drug TroVax, says cash burn in line	Proactive Investors.co.uk:  Nov 20 2009 2:47PM Matching: oxford biomedica
TechMARK movers: Psion shares fall despite positive statement	Find:  Nov 19 2009 7:15PM Matching: oxford biomedica
TechMARK movers: Psion shares fall despite positive statement	ShareCast:  Nov 19 2009 5:11PM Matching: oxford biomedica
TechMARK movers: Psion shares fall despite positive statement	Digital Look:  Nov 19 2009 4:09PM Matching: oxford biomedica
TechMARK movers: Cautiously optimistic Dimension	Find:  Nov 18 2009 5:41PM Matching: oxford biomedica
Promote your company here: BioNewsCast - Press Release Distribution	→View more Oxford BioMedica news.

Oxford BioMedica Clinical Trials:
Study to Evaluate Safety and Biological Activity of TroVax® Vaccine Given in Conjunction With IL-2 to Treat Locally Advanced or Metastatic Renal Cell Carcinoma

Oxford BioMedica Patents:
US Patent No.	Title
7601698	Polypeptide
6852703	Tumor targeted vector
6818209	Retroviral delivery system
6808922	Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
6800281	Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
→View more Oxford BioMedica patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 303 times since April 2007, the link to the organisation's website has been followed 56 times

Search for more companies in Oxford

Search for more companies in Oxfordshire

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Oxford BioMedica